Blurbs

Analysts Offer Insights on Healthcare Companies: Centene (CNC), Ionis Pharmaceuticals (IONS) and Intellia Therapeutics (NTLA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Centene (CNCResearch Report), Ionis Pharmaceuticals (IONSResearch Report) and Intellia Therapeutics (NTLAResearch Report).

Centene (CNC)

In a report released today, Matthew Borsch from BMO Capital maintained a Buy rating on Centene, with a price target of $105.00. The company’s shares closed last Tuesday at $80.86.

According to TipRanks.com, Borsch is a 3-star analyst with an average return of 3.6% and a 53.7% success rate. Borsch covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Acadia Healthcare, and Encompass Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Centene with a $95.91 average price target, a 18.6% upside from current levels. In a report issued on June 16, Loop Capital Markets also initiated coverage with a Buy rating on the stock with a $100.00 price target.

See the top stocks recommended by analysts >>

Ionis Pharmaceuticals (IONS)

BMO Capital analyst Gary Nachman reiterated a Buy rating on Ionis Pharmaceuticals today and set a price target of $70.00. The company’s shares closed last Tuesday at $37.41.

According to TipRanks.com, Nachman is ranked 0 out of 5 stars with an average return of -9.1% and a 38.9% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Aquestive Therapeutics, and Jazz Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $51.18 average price target, implying a 36.8% upside from current levels. In a report issued on June 10, Piper Sandler also maintained a Buy rating on the stock with a $55.00 price target.

Intellia Therapeutics (NTLA)

In a report released today, Kostas Biliouris from BMO Capital maintained a Hold rating on Intellia Therapeutics, with a price target of $54.00. The company’s shares closed last Tuesday at $44.48, close to its 52-week low of $37.08.

According to TipRanks.com, Biliouris is a 3-star analyst with an average return of 12.9% and a 85.7% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Crispr Therapeutics AG, and Precision BioSciences.

Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $99.64.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CNC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos